Insmed (INSM) News Today → A letter is coming from the 'Bureau of the Fiscal Service'. (From Stansberry Research) (Ad) Free INSM Stock Alerts $24.77 -0.33 (-1.31%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 7:59 PM | finance.yahoo.comInsider Sale: Chief Medical Officer Martina Flammer Sells Shares of Insmed Inc (INSM)May 17 at 7:58 AM | marketbeat.comPrincipal Financial Group Inc. Raises Stock Holdings in Insmed Incorporated (NASDAQ:INSM)Principal Financial Group Inc. raised its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,359,563 shares of the biopharmaceutical company's stock afteMay 17 at 6:36 AM | americanbankingnews.comSara Bonstein Sells 11,088 Shares of Insmed Incorporated (NASDAQ:INSM) StockMay 17 at 5:34 AM | americanbankingnews.comWilliam Lewis Sells 22,198 Shares of Insmed Incorporated (NASDAQ:INSM) StockMay 17 at 4:38 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $49.00May 17 at 2:12 AM | americanbankingnews.comQ2 2024 Earnings Forecast for Insmed Incorporated (NASDAQ:INSM) Issued By HC WainwrightMay 16 at 3:17 PM | marketbeat.comTruist Financial Reiterates "Buy" Rating for Insmed (NASDAQ:INSM)Truist Financial reaffirmed a "buy" rating and set a $48.00 target price on shares of Insmed in a report on Thursday.May 16 at 1:38 PM | insidertrades.comInsider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 5,088 Shares of StockMay 16 at 7:26 AM | marketbeat.comQ2 2024 EPS Estimates for Insmed Incorporated Raised by Analyst (NASDAQ:INSM)Insmed Incorporated (NASDAQ:INSM - Free Report) - Research analysts at HC Wainwright increased their Q2 2024 earnings per share estimates for shares of Insmed in a research report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will poMay 16 at 5:54 AM | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Insmed (NASDAQ:INSM)May 15 at 8:27 PM | marketbeat.comInsmed Incorporated (NASDAQ:INSM) Insider Sells $129,591.36 in StockInsmed Incorporated (NASDAQ:INSM - Get Free Report) insider John Drayton Wise sold 5,088 shares of the company's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $25.47, for a total value of $129,591.36. Following the completion of the transaction, the insider now directly owns 123,259 shares in the company, valued at $3,139,406.73. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.May 15 at 4:01 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $36.00 at MizuhoMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Insmed on Strong TPIP Trial Results and High Anticipation for ASPEN Trial OutcomesMay 14, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $52.00 price target on shares of Insmed in a research note on Tuesday.May 14, 2024 | americanbankingnews.comInsmed (NASDAQ:INSM) Price Target Increased to $43.00 by Analysts at Morgan StanleyMay 14, 2024 | marketbeat.comInsmed Incorporated (NASDAQ:INSM) Shares Sold by Swiss National BankSwiss National Bank reduced its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 10.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 269,200 shares of the biopharmaceutical company's sMay 14, 2024 | americanbankingnews.comInsmed (NASDAQ:INSM) Lifted to Hold at StockNews.comMay 13, 2024 | marketbeat.comMizuho Boosts Insmed (NASDAQ:INSM) Price Target to $36.00Mizuho upped their price objective on Insmed from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Monday.May 13, 2024 | markets.businessinsider.comInsmed (INSM) Receives a Buy from Stifel NicolausMay 12, 2024 | marketbeat.comEssex Investment Management Co. LLC Sells 40,412 Shares of Insmed Incorporated (NASDAQ:INSM)Essex Investment Management Co. LLC cut its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 27.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 108,007 shares of the biopharmaceutical company's stocMay 11, 2024 | finance.yahoo.comInsmed Incorporated (NASDAQ:INSM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 11, 2024 | americanbankingnews.comInsmed Sees Unusually High Options Volume (NASDAQ:INSM)May 10, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Posts Earnings Results, Beats Expectations By $0.16 EPSInsmed (NASDAQ:INSM - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.22) by $0.16. The company had revenue of $75.50 million during the quarter, compared to analysts' expectations of $77.76 million. During the same period last year, the firm posted ($1.17) earnings per share. Insmed's revenue was up 15.8% on a year-over-year basis.May 10, 2024 | marketbeat.comInsmed Target of Unusually High Options Trading (NASDAQ:INSM)Insmed Incorporated (NASDAQ:INSM - Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 20,174 call options on the stock. This is an increase of approximately 1,592% compared to the typical volume of 1,192 call options.May 10, 2024 | benzinga.comThis Is What Whales Are Betting On InsmedMay 10, 2024 | finance.yahoo.comInsmed Inc (INSM) Reports Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows Amidst Clinical ...May 10, 2024 | finance.yahoo.comInsmed Incorporated (NASDAQ:INSM) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comInsmed (NASDAQ:INSM) PT Raised to $43.00 at Morgan StanleyMorgan Stanley raised their price target on Insmed from $40.00 to $43.00 and gave the stock an "overweight" rating in a research note on Friday.May 10, 2024 | finance.yahoo.comInsmed First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Shares Gap Up to $26.00Insmed (NASDAQ:INSM) Shares Gap Up to $26.00May 9, 2024 | investorplace.comINSM Stock Earnings: Insmed Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | prnewswire.comInsmed Reports First-Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | msn.comStocks Slip Before the Open on Higher Bond Yields and Weak Earnings, BoE Decision in FocusMay 8, 2024 | markets.businessinsider.comHere's what to expect from Insmed's earningsMay 7, 2024 | finance.yahoo.comWe Think Some Shareholders May Hesitate To Increase Insmed Incorporated's (NASDAQ:INSM) CEO CompensationMay 7, 2024 | prnewswire.comInsmed To Present at the BofA Securities Health Care Conference 2024May 7, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Cut to "Sell" at StockNews.comStockNews.com lowered shares of Insmed from a "hold" rating to a "sell" rating in a research report on Monday.May 3, 2024 | prnewswire.comInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 29, 2024 | marketbeat.comabrdn plc Buys New Shares in Insmed Incorporated (NASDAQ:INSM)abrdn plc bought a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the biopharmaceutical company's stock, valued at approximately $April 27, 2024 | marketbeat.comJennison Associates LLC Makes New $3.75 Million Investment in Insmed Incorporated (NASDAQ:INSM)Jennison Associates LLC purchased a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 120,831 shares of the biopharmaceutical company's stock, valued at approximately $3,745,000. JennisonApril 25, 2024 | investing.comInsmed shares upgraded on growth potentialApril 25, 2024 | prnewswire.comInsmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024April 24, 2024 | msn.comTruist Securities Initiates Coverage of Insmed (INSM) with Buy RecommendationApril 23, 2024 | marketbeat.comTruist Financial Begins Coverage on Insmed (NASDAQ:INSM)Truist Financial assumed coverage on Insmed in a research report on Tuesday. They set a "buy" rating and a $48.00 price target on the stock.April 22, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Sees Large Volume IncreaseInsmed (NASDAQ:INSM) Sees Unusually-High Trading VolumeApril 20, 2024 | msn.comActress Jane Seymour on the Effects of “Unseenism” and the #1 Way To Fight It: “Health Is Everything”April 19, 2024 | marketbeat.comKnights of Columbus Asset Advisors LLC Raises Stock Position in Insmed Incorporated (NASDAQ:INSM)Knights of Columbus Asset Advisors LLC raised its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 101.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 228,783 shares of thApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)April 11, 2024 | marketbeat.comBarclays Increases Insmed (NASDAQ:INSM) Price Target to $40.00Barclays increased their target price on Insmed from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Thursday.April 10, 2024 | finance.yahoo.comWhat Makes Insmed (INSM) a Lucrative Investment? Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. INSM Media Mentions By Week INSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INSM News Sentiment▼0.470.52▲Average Medical News Sentiment INSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INSM Articles This Week▼324▲INSM Articles Average Week Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HUTCHMED News Today Axsome Therapeutics News Today Crinetics Pharmaceuticals News Today Prestige Consumer Healthcare News Today Perrigo News Today Alkermes News Today Ultragenyx Pharmaceutical News Today Biohaven News Today Summit Therapeutics News Today Nuvalent News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INSM) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
